Xeris to Join Upcoming Investor Conferences

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a forward-thinking biopharmaceutical firm based in Chicago, is dedicated to enhancing patient outcomes through the development and commercialization of innovative therapeutic products. The company recently announced its participation in several upcoming industry events, where senior management will engage with stakeholders.

The first event on the agenda is the 2024 Wells Fargo Healthcare Conference in Boston, MA, where Xeris will hold meetings exclusively on September 4, 2024. This will be followed by the H.C. Wainwright 26th Annual Global Investor Conference in New York, NY, scheduled for September 10, 2024. At this conference, Xeris will not only conduct meetings but also participate in a fireside chat at 3:30 pm ET. Lastly, the company will attend the 2024 Cantor Global Healthcare Conference, also in New York, NY, with meetings planned for September 18, 2024. Those interested in arranging one-on-one meetings are advised to contact the conference sponsors directly.

Xeris is renowned for its commitment to patient-centric solutions across various therapeutic areas. The company has successfully brought three major products to market. Gvoke®, a ready-to-use liquid glucagon, is designed to treat severe hypoglycemia. Keveyis® is a reliable treatment for primary periodic paralysis, while Recorlev® addresses endogenous Cushing’s syndrome. These products highlight Xeris’s focus on specialized medical needs and its capabilities in innovative drug formulation.

The company leverages its proprietary technologies, XeriSol™ and XeriJect®, to foster the development of both its own pipeline and partnered programs. These formulation sciences are integral to its strategy for sustained product development and commercial achievements. By utilizing these technologies, Xeris aims to enhance the stability, solubility, and delivery of therapeutic agents, thereby improving patient adherence and outcomes.

In summary, Xeris Biopharma Holdings, Inc. continues to make significant strides in the healthcare sector through its dedication to innovative therapeutics and its active engagement with the investor and medical communities. The company's ongoing efforts to participate in key industry conferences underscore its commitment to maintaining strong relationships with stakeholders and advancing its mission to improve patient lives.